This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Zacks News
Atreca (BCEL) Suspends Lead Drug Evaluation, Stock Falls 37%
by Zacks Equity Research
Atreca (BCEL) suspends the development of only pipeline candidate, ATRC-101, in clinical evaluation, as part of its business restructuring efforts and cuts headcount by 40%. The stock falls 37%.
Here's Why Atreca, Inc. (BCEL) Is a Great 'Buy the Bottom' Stock Now
by Zacks Equity Research
Atreca, Inc. (BCEL) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Are Medical Stocks Lagging ASLAN Pharmaceuticals (ASLN) This Year?
by Zacks Equity Research
Here is how ASLAN Pharmaceuticals Ltd. (ASLN) and Atreca, Inc. (BCEL) have performed compared to their sector so far this year.
Can Atreca, Inc. (BCEL) Climb 310% to Reach the Level Wall Street Analysts Expect?
by Zacks Equity Research
The consensus price target hints at a 310.2% upside potential for Atreca, Inc. (BCEL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Has Atreca, Inc. (BCEL) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Atreca, Inc. (BCEL) and Indivior PLC (INVVY) have performed compared to their sector so far this year.
Atreca, Inc. (BCEL) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Atreca, Inc. (BCEL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
What's in Store for Zomedica (ZOM)This Earnings Season?
by Zacks Equity Research
Zomedica (ZOM) may provide an update on Truforma commercialization progress when it reports fourth-quarter 2020 results.
What's in Store for Mallinckrodt (MNKKQ)This Earnings Season?
by Zacks Equity Research
Negative impact of COVID-19 is likely to have hurt sales of Mallinckrodt (MNKKQ) during the fourth quarter. Investors are likely to focus on bankruptcy proceedings during the earning call.
What Makes Atreca, Inc. (BCEL) a New Buy Stock
by Zacks Equity Research
Atreca, Inc. (BCEL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Atreca, Inc. (BCEL) Upgraded to Buy: Here's Why
by Zacks Equity Research
Atreca, Inc. (BCEL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
All You Need to Know About Atreca, Inc. (BCEL) Rating Upgrade to Buy
by Zacks Equity Research
Atreca, Inc. (BCEL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.